Matrix

Phase 1Biologic

MMaule Stem Cell Research Institute, Inc.

Matrix is one of 33 biologic programs targeting Interstitial Lung Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial Lung DiseaseRecruiting

Interstitial Lung DiseasePhase 1

Recruiting

Competition

Competitive Landscape

38 competitors in Interstitial Lung Disease

#DrugCompanyPhaseTrials

Rituxan

Roche

Approved

5 2

Tracleer

Johnson & Johnson

Approved

3 3

Medrol

Pfizer

Approved

2 4

Trexall

Jazz Pharmaceuticals

Approved

2 5

Esbriet

LLegacy Health System

Approved

5 6

Cytoxan

BBaxter Healthcare Corporation

Approved

3 7

Actemra

CCelltrion

Approved

2 8

Cellcept

Roche

Phase 3

4 9

Imuran

LLegacy Health System

Ofev

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Interstitial Lung Disease

NCT07372989

Clinical

Trials by Indication[1]

Interstitial Lung Disease1 trial

Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease

Recruiting·MMaule Stem Cell Research Institute, Inc.·Phase 1·NCT07372989·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Matrix. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Matrix compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Matrix. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Maule Stem Cell Research Institute, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: MMaule Stem Cell Research Institute, Inc.

Matrix

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Interstitial Lung Disease1 trial

References

Drug Info

Quick Facts

Related News